Application of the adverse outcome pathway to identify molecular changes in prenatal brain programming induced by IUGR: Discoveries after EGCG exposure

dc.contributor.authorKühne, Britta Anna
dc.contributor.authorTeixidó Condomines, Elisabet
dc.contributor.authorEttcheto Arriola, Miren
dc.contributor.authorPuig i Miquel, Teresa
dc.contributor.authorPlanas, Marta
dc.contributor.authorFeliu, Lidia
dc.contributor.authorPla, Laura
dc.contributor.authorCampuzano Uceda, María Victoria
dc.contributor.authorGratacós Solsona, Eduard
dc.contributor.authorFritsche, Ellen
dc.contributor.authorIlla Armengol, Míriam
dc.contributor.authorBarenys Espadaler, Marta
dc.date.accessioned2024-07-24T07:51:25Z
dc.date.available2024-07-24T07:51:25Z
dc.date.issued2022-11-09
dc.date.updated2024-07-24T07:51:30Z
dc.description.abstractFollowing a multi-disciplinary approach integrating information from several experimental models we have collected new evidence supporting, expanding and redesigning the AOP "Disrupted laminin/int-β1 interaction leading to decreased cognitive function". Investigations in vitro in rabbit and rat neurospheres and in vivo in mice exposed to EGCG (epigallocatechin-gallate) during neurodevelopment are combined with in vitro evaluations in neural progenitor cells overexpressing int-β1 and literature information from int-β1 deficiency models. We have discovered for the first time that neural progenitor cells from intrauterine growth restricted (IUGR) animals overexpress int-β1 at gene and protein level and due to this change in prenatal brain programming they respond differently than control neurospheres to the exposure of EGCG, a compound triggering neural progenitor cell migration alterations. We have also identified that EGCG developmental exposure has deleterious effects on neuronal branching and arborization in vitro and in vivo. Our results warn that a thorough developmental neurotoxicity characterization of this and other catechin-based food supplements is needed before recommending their consumption during pregnancy.
dc.format.extent1 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec726766
dc.identifier.issn0278-6915
dc.identifier.urihttps://hdl.handle.net/2445/214689
dc.language.isoeng
dc.publisherElsevier Ltd
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.fct.2022.113506
dc.relation.ispartofFood and Chemical Toxicology, 2022, vol. 170, num.113506
dc.relation.urihttps://doi.org/10.1016/j.fct.2022.113506
dc.rightscc-by-nc-nd (c) Britta Anna Kühne, et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject.classificationCreixement fetal
dc.subject.classificationNeurogenètica
dc.subject.classificationMedicina prenatal
dc.subject.otherFetal growth
dc.subject.otherNeurogenetics
dc.subject.otherPrenatal medicine
dc.titleApplication of the adverse outcome pathway to identify molecular changes in prenatal brain programming induced by IUGR: Discoveries after EGCG exposure
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
253801.pdf
Mida:
6.58 MB
Format:
Adobe Portable Document Format